(NASDAQ: CGTX) Cognition Therapeutics's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 64.17%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.07%.
Cognition Therapeutics's revenue in 2025 is $0.On average, 1 Wall Street analysts forecast CGTX's revenue for 2027 to be $2,598,525,626, with the lowest CGTX revenue forecast at $2,598,525,626, and the highest CGTX revenue forecast at $2,598,525,626. On average, 1 Wall Street analysts forecast CGTX's revenue for 2028 to be $1,134,104,912, with the lowest CGTX revenue forecast at $1,134,104,912, and the highest CGTX revenue forecast at $1,134,104,912.
In 2029, CGTX is forecast to generate $6,222,083,778 in revenue, with the lowest revenue forecast at $6,222,083,778 and the highest revenue forecast at $6,222,083,778.